Etude MONARCH-2 dngn 10.12.2014
CRITERES D’INCLUSION / EXCLUSION
Have a diagnosis of HR+, HER2- breast cancer
To fulfill the requirement of HR+ disease, a breast cancer must express, by immunohistochemistry (IHC), at least 1 of the
hormone receptors (estrogen receptor [ER] or progesterone receptor [PgR]) as defined in the relevant American Society of
Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines (Hammond et al. 2010)
To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy,
overexpression of HER2 by either IHC or in-situ hybridization as defined in the relevant ASCO / CAP Guidelines (Wolff et al.
2013). Although not required as a protocol procedure, a patient with a new metastatic lesion should be considered for biopsy
whenever possible to reassess HER2 status prior to study entry if clinically indicated
Have either locally advanced disease not amenable to curative treatment by surgery or metastatic
disease. In addition, patients must fulfill 1 of the following criteria:
Relapsed with radiologic evidence of progression on neoadjuvant or adjuvant endocrine therapy
Relapsed with radiologic evidence of progression within 1 year from completion of adjuvant endocrine therapy
Relapsed with radiologic evidence of progression more than 1 year from completion of adjuvant endocrine therapy and then
subsequently relapsed with radiologic evidence of progression after no more than first-line endocrine therapy (with either an
antiestrogen or an aromatase inhibitor) for metastatic disease
Presented de novo with locally advanced or metastatic disease and not received any prior endocrine therapy
Presented de novo with locally advanced or metastatic disease and then relapsed with radiologic evidence of progression after no
more than first-line endocrine therapy (with either an antiestrogen or an aromatase inhibitor)
Have postmenopausal status due to either surgical/natural menopause or ovarian suppression
(initiated at least 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH)
agonist such as goserelin.
Postmenopausal status due to surgical/natural menopause requires at least 1 of the following:
Prior bilateral oophorectomy
Age ≥60 years
Age <60 years and amenorrheic for at least 12 months (in the absence of chemotherapy, tamoxifen, toremifene, or ovarian
suppression) and follicle-stimulating hormone (FSH) and estradiol levels in the postmenopausal range
Have a negative serum pregnancy test at baseline (within 14 days prior to randomization) and agree
to use medically approved precautions to prevent pregnancy during the study and for 12 weeks
following the last dose of LY2835219 if postmenopausal status is due to ovarian suppression with a
GnRH agonist
Have either measurable disease or nonmeasurable bone only disease. Measurable and
nonmeasurable disease are defined according to the Response Evaluation Criteria in Solid Tumors
(RECIST Version 1.1 [v1.1], Eisenhauer et al. 2009; refer to Attachment 5). Nonmeasurable bone only
disease may include any of the following: blastic bone lesions, lytic bone lesions without a
measurable soft tissue component, or mixed lytic-blastic bone lesions without a measurable soft
tissue component.
Are female and >18 years of age
Have given written informed consent prior to any study-specific procedures
Have adequate organ function, including:
Absolute neutrophil count ≥1.5 × 109/L, platelets 100 ×
109/L, and hemoglobin ≥8 g/dL. Patients may receive
erythrocyte transfusions to achieve this hemoglobin level at
the discretion of the investigator; however, initial study drug
treatment must not begin earlier than the day after the
erythrocyte transfusion
Bilirubin ≤1.5 times upper limit of normal (ULN) and
alanine aminotransferase (ALT) ≤3.0 times ULN
Serum creatinine ≤1.5 times ULN
Have a performance status ≤1 on the ECOG scale
Have discontinued previous therapies for cancer (including specifically, aromatase inhibitors, anti-